Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 10/20 | 0.39 |
| ▸ | GGPS1 | O95749 | 7/20 | 0.39 |
| ▸ | SMPD1 | P17405 | 3/20 | 0.38 |
| ▸ | CES2 | O00748 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23264369 | 0.79 | TSHR (0.38) | FDPSGGPS1SMPD1CES2 | |
| SCHEMBL7852352 | 0.78 | SMPD1 (0.40) | FDPSGGPS1SMPD1CES2 | |
| SCHEMBL5159203 | 0.73 | FDPS (0.43) | FDPSGGPS1SMPD1CES2 | |
| SCHEMBL9775043 | 0.73 | SMPD1 (0.52) | FDPSGGPS1SMPD1CES2 | |
| SCHEMBL1983154 | 0.73 | FDPS (0.39) | FDPSGGPS1SMPD1 | |
| SCHEMBL136025 | 0.72 | — | — | |
| SCHEMBL30765031 | 0.71 | SMPD1 (0.45) | FDPSGGPS1SMPD1 | |
| SCHEMBL27714683 | 0.71 | SMPD1 (0.45) | FDPSGGPS1SMPD1 | |
| SCHEMBL7523594 | 0.71 | SMPD1 (0.55) | FDPSGGPS1SMPD1 | |
| SCHEMBL4582470 | 0.71 | SMPD1 (0.55) | FDPSGGPS1SMPD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2337544-A2 | USE OF MATRIX METALLOPROTEINASE INHIBITORS IN SKIN CARE | Living Proof, Inc. (US) | 2011-06-29 | — | — | EP | disclosed |
| US-20090068255-A1 | USE OF MATRIX METALLOPROTEINASE INHIBITORS IN SKIN CARE | LIVING PROOF, INC. | 2009-03-12 | — | — | US | disclosed |
| WO-2008134712-A2 | USE OF MATRIX METALLOPROTEINASE INHIBITORS IN SKIN CARE | LIVING PROOF, INC. (US) | 2008-11-06 | — | — | WO | disclosed |
| WO-2008070368-A2 | METHODS AND COMPOSITIONS FOR SKIN CARE | LIVING PROOF, INC. (US) | 2008-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090068255-A1 | USE OF MATRIX METALLOPROTEINASE INHIBITORS IN SKIN CARE | MMP1, MMP9, MMP17 | FDPS 4797/4885GGPS1 4837/4885SMPD1 307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.